MABIMMUNE - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 85683762
Serial Number
85683762
Registration Number
4896966
Word Mark
MABIMMUNE
Status
700 - Registered
Status Date
2016-02-09
Filing Date
2012-07-22
Registration Number
4896966
Registration Date
2016-02-09
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2015-11-24
Attorney Name
Law Office Assigned Location Code
L20
Employee Name
VAGHANI, MAYUR C
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Goods and Services
Chemicals, namely, chemical preparations containing monoclonal antibodies for biological assays; industrial chemicals containing monoclonal antibodies; chemical preparations containing monoclonal antibodies for scientific purposes; chemical preparations containing monoclonal antibodies for use in photography; biological materials, namely, biological tissue and cell cultures containing monoclonal antibodies other than for medical or veterinary purposes, inoculants in the nature of biological microorganisms containing monoclonal antibodies used for biomedical research; biological preparations, namely, biological tissue and cell cultures containing monoclonal antibodies other than for medical or veterinary purposes, inoculants containing monoclonal antibodies in the nature of biological microorganisms used for biomedical research; peptides for chemicals and foodstuff, namely, peptide substrates containing monoclonal antibodies used in analyzing and detecting certain biomarkers for laboratory or research use; polypeptides, namely, peptide substrates containing monoclonal antibodies used in analyzing and detecting certain biomarkers for laboratory or research use, protein antibodies, namely, monoclonal antibodies containing monoclonal antibodies for in vitro or in-vivo scientific or research use, antibody reagents containing monoclonal antibodies used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; diagnostic preparations containing monoclonal antibodies for scientific use; Biological compounds, namely, epitopes containing monoclonal antibodies in the nature of enzyme or mis-folded proteins for use in the pre-clinical research and development of pharmaceutical preparations such as antibodies or active peptides
Goods and Services
Skin care preparations containing monoclonal antibodies, namely, chemical peels for skin, anti-aging topical creams, anti-wrinkle topical creams, non-medicated lotions which are indicated specifically for reducing scar formation, topical ointments containing monoclonal antibodies indicated for accelerating the healing process or alleviating the symptoms of burns, namely, non-medicated ointments for the prevention and treatment of sunburn, topical beauty products, namely, cosmetics containing monoclonal antibodies
Goods and Services
Pharmaceutical preparations containing monoclonal antibodies for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; pharmaceutical preparations containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; veterinary preparations containing monoclonal antibodies for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; veterinary preparations containing monoclonal antibodies for metabolic diseases including diabetes mellitus; tumor suppressing agents containing monoclonal antibodies; preparations containing monoclonal antibodies for treating neurodegenerative diseases; immunogenics, namely, pharmaceutical preparations containing monoclonal antibodies for inducing immune responses for the treatment of oncology indications including lymphomas, sarcomas, carcinomas, leukemias, bacterial infections, parasitic disease; vaccines containing monoclonal antibodies; antibodies containing monoclonal antibodies, namely, for treatment of anti-inflammatory, cardiovascular, oncological, and dermatological indications; active epitopes in the form of a pharmaceutical preparation containing monoclonal antibodies which modulate the biological activity of drug targets in-vivo; synthetic peptides containing monoclonal antibodies for pharmaceutical purposes for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; synthetic peptides for pharmaceutical purposes containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; sanitary preparations containing monoclonal antibodies for medical purposes; biological preparations for medical purposes containing monoclonal antibodies for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; biological preparations for medical purposes containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; biocides containing monoclonal antibodies; diagnostic preparations for medical or veterinary purposes containing monoclonal antibodies; sanitary towels containing monoclonal antibodies; dietetic food, namely, pasta, crackers, bread adapted for medical purposes containing monoclonal antibodies; dietetic beverages, namely, tea, vitamin fortified beverages, protein shakes adapted for medical purposes containing monoclonal antibodies; algaecide chemicals containing monoclonal antibodies for swimming pools; biological tissue containing monoclonal antibodies such as bone, skin, blood vessels, cartilage, muscle, teeth, extracellular matrix, and heart valve tissue intended for subsequent implantation; synthetic peptides and polypeptides containing monoclonal antibodies for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; synthetic peptides and polypeptides for the treatment of metabolic diseases including diabetes mellitus; chemicals, namely, chemical preparations for pharmaceutical or medical purposes containing monoclonal antibodies, namely, for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; pharmaceutical preparations, namely, medicated scar-reducing lotions containing monoclonal antibodies; burn relief medication ointments containing monoclonal antibodies; Chemicals, namely, chemical preparations containing monoclonal antibodies for medical kits and tests, namely, diagnostic blood tests, companion diagnostics, and blood tests to determine the efficacy of the treatment strategy including both plasma and serum based assays for metabolic, cardiovascular, oncological, and inflammatory diseases
Goods and Services
Physical examination featuring monoclonal antibodies, namely, physical fitness training services, physical performance monitoring in the nature of physical fitness consultation
Goods and Services
Testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs containing monoclonal antibodies; consultancy and providing information of testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs containing monoclonal antibodies; testing, inspection or research of medical treatment and technique containing monoclonal antibodies; research in the field of biotechnology and antibodies containing monoclonal antibodies; providing information of testing, inspection or research of medical treatment and technique containing monoclonal antibodies; scientific research of health care related to monoclonal antibodies; testing, inspection or research of biology related to monoclonal antibodies; computer software design, computer programming, or maintenance of computer software featuring monoclonal antibodies; computer hardware design and development related to monoclonal antibodies; computer software design and development related to monoclonal antibodies; consultancy and providing information in the field of development of pharmaceutical preparations containing monoclonal antibodies; consultancy and providing information in the field of biomedical research related to monoclonal antibodies
Goods and Services
Medical services featuring monoclonal antibodies; medical services featuring monoclonal antibodies in the field of immunity, cardiology, rheumatology, oncology, pneumology, neurology; providing medical information featuring monoclonal antibodies; medical services, namely, conducting physical medical examinations featuring monoclonal antibodies in the fields of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; medical services featuring monoclonal antibodies, namely, conducting physical medical examinations in the fields of metabolic diseases including diabetes mellitus; preparation and dispensing of medications containing monoclonal antibodies; dietary and nutritional guidance featuring monoclonal antibodies; providing information of health care featuring monoclonal antibodies; consulting in the field of medicine, occupational therapy, and nutrition featuring monoclonal antibodies; veterinary services featuring monoclonal antibodies; beauty salons featuring monoclonal antibodies; animal sanitary services, namely, animal grooming services, animal health care, and veterinary services in the nature of euthanasia of animals featuring monoclonal antibodies; health care featuring monoclonal antibodies; consultancy and providing information in the fields of medical imaging, diagnostic properties of pharmaceuticals, and medical care related to human physiology and pathophysiology featuring monoclonal antibodies; pharmaceutical consultation featuring monoclonal antibodies; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals featuring monoclonal antibodies; physical performance monitoring in the nature of physical therapy or physiotherapy services featuring monoclonal antibodies; ergometry, namely, nutrition counseling featuring monoclonal antibodies; ergometry in the nature of health assessment, namely, blood tests featuring monoclonal antibodies for the evaluation of physical fitness or response to training
Translation of Words in Mark
The wording "MABIMMUNE" has no meaning in a foreign language.
Classification Information
International Class
001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes
001, 005, 006, 010, 026, 046
Class Status Code
6 - Active
Class Status Date
2012-07-27
Primary Code
001
International Class
003 - Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices. - Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices.
US Class Codes
001, 004, 006, 050, 051, 052
Class Status Code
6 - Active
Class Status Date
2013-05-16
Primary Code
003
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2012-07-27
Primary Code
005
International Class
041 - Education; providing of training; entertainment; sporting and cultural activities. - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes
100, 101, 107
Class Status Code
6 - Active
Class Status Date
2013-05-16
Primary Code
041
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2012-07-27
Primary Code
042
International Class
044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2012-07-27
Primary Code
044
Current Trademark Owners
Party Name
Party Type
31 - 1st New Owner Entered After Registration
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
31 - 1st New Owner Entered After Registration
Address
Please log in with your Justia account to see this address.
Party Type
30 - Original Registrant
Address
Please log in with your Justia account to see this address.
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Janice Housey
Address
Please log in with your Justia account to see this address.
Foreign Application Information
Filing DateApplication NumberCountryForeign Priority Claim In
SwitzerlandFalse
SwitzerlandFalse
Trademark Events
Event DateEvent Description
2012-07-25NEW APPLICATION ENTERED IN TRAM
2012-07-27NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2012-08-13TEAS VOLUNTARY AMENDMENT RECEIVED
2012-08-13TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
2012-11-15ASSIGNED TO EXAMINER
2012-11-16NON-FINAL ACTION WRITTEN
2012-11-16NON-FINAL ACTION E-MAILED
2012-11-16NOTIFICATION OF NON-FINAL ACTION E-MAILED
2013-05-15TEAS RESPONSE TO OFFICE ACTION RECEIVED
2013-05-15CORRESPONDENCE RECEIVED IN LAW OFFICE
2013-05-16TEAS/EMAIL CORRESPONDENCE ENTERED
2013-06-06FINAL REFUSAL WRITTEN
2013-06-06FINAL REFUSAL E-MAILED
2013-06-06NOTIFICATION OF FINAL REFUSAL EMAILED
2013-12-06EXPARTE APPEAL RECEIVED AT TTAB
2013-12-06JURISDICTION RESTORED TO EXAMINING ATTORNEY
2013-12-06EX PARTE APPEAL-INSTITUTED
2013-12-06TEAS REQUEST FOR RECONSIDERATION RECEIVED
2013-12-30ASSIGNED TO LIE
2014-01-06CORRESPONDENCE RECEIVED IN LAW OFFICE
2014-01-06TEAS/EMAIL CORRESPONDENCE ENTERED
2014-01-23EXAMINERS AMENDMENT -WRITTEN
2014-01-23EXAMINERS AMENDMENT E-MAILED
2014-01-23NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
2014-01-23EXAMINER'S AMENDMENT ENTERED
2014-01-23APPROVED FOR PUB - PRINCIPAL REGISTER
2014-01-25LAW OFFICE PUBLICATION REVIEW COMPLETED
2014-02-10WITHDRAWN FROM PUB - OG REVIEW QUERY
2014-02-27PREVIOUS ALLOWANCE COUNT WITHDRAWN
2014-03-06NON-FINAL ACTION WRITTEN
2014-03-06NON-FINAL ACTION E-MAILED
2014-03-06NOTIFICATION OF NON-FINAL ACTION E-MAILED
2014-07-23TEAS RESPONSE TO OFFICE ACTION RECEIVED
2014-07-23CORRESPONDENCE RECEIVED IN LAW OFFICE
2014-07-24TEAS/EMAIL CORRESPONDENCE ENTERED
2014-07-28APPROVED FOR PUB - PRINCIPAL REGISTER
2014-07-28EXPARTE APPEAL TERMINATED
2014-07-31LAW OFFICE PUBLICATION REVIEW COMPLETED
2014-08-13NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2014-09-02PUBLISHED FOR OPPOSITION
2014-09-02OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2014-10-28NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2014-11-19TEAS DELETE 1(B) BASIS RECEIVED
2015-01-15CASE ASSIGNED TO INTENT TO USE PARALEGAL
2015-04-21TEAS EXTENSION RECEIVED
2015-04-21EXTENSION 1 FILED
2015-04-21EXTENSION 1 GRANTED
2015-04-23NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2015-08-27REVIEW OF CORRESPONDENCE COMPLETE
2015-10-09TEAS PETITION TO AMEND BASIS RECEIVED
2015-10-14ASSIGNED TO PETITION STAFF
2015-10-15PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
2015-10-16NOTICE OF ALLOWANCE CANCELLED
2015-10-16NOA CANCELLED; REPUBLICATION REQUIRED
2015-11-04NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2015-11-24PUBLISHED FOR OPPOSITION
2015-11-24OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2016-02-09REGISTERED-PRINCIPAL REGISTER
2016-03-10TEAS CHANGE OF CORRESPONDENCE RECEIVED
2020-05-13AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
2021-02-09COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
2021-07-21TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2021-07-21ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2021-07-21TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
2021-07-21TEAS CHANGE OF CORRESPONDENCE RECEIVED